期刊文献+

TNP-470抑制小鼠恶性腹腔积液形成的实验研究 被引量:2

An experimental study of angiogenesis inhibitor TNP-470 on the formation of malignant ascites in mice
下载PDF
导出
摘要 目的 :研究血管生成抑制剂TNP 4 70对小鼠恶性腹腔积液形成的抑制作用。方法 :将小鼠肝癌腹水型细胞系Hca F2 5接种于小鼠腹腔 (2× 10 5/鼠 )。将 10 0只小鼠随机分成对照组 (0 9%NS) ,化疗组 (DDP 1mg/kg) ,TNP 4 70低、中、高剂量组 (30mg/kg、6 0mg/kg、90mg/kg)。自第 2天起分别腹腔内给药 (0 2ml/鼠 ) ,隔日给药 ,共 7次。第 15天处死部分小鼠测各项指标 ,余小鼠观察生存期。结果 :化疗组 ,TNP 4 70低、中、高剂量组的腹水抑制率分别为 74 77% ,5 2 33%、80 11%和 92 89% ;腹膜瘤结节的形成率分别为 10 0 % ,70 %、80 %、5 0 %和 30 %。在生存时间上 ,各治疗组较对照组明显延长生存期 (P <0 0 5 )。结论 :TNP 4 70具有抑制小鼠恶性腹腔积液的形成和延长小鼠生存时间的作用。 Objective:The inhibition effect of angiogenesis inhibitor TNP 470 was investigated in a murine malignant ascites model.Methods:Hca F25 cancer cell (2×10 5/mouse) were inoculated in the murine peritoneal cavity. There are 100 mice that were randomized into 5 groups. From the 2 nd day, the control group was given 0 9% NS, the three treated groups were given 30 mg/kg, 60 mg/kg and 90 mg/kg of TNP 470 respectively, the chemotherapy group was given DDP 1 mg/kg. Each was injected i.p. every other day for 7 times. On the 15 th day, half of them were killed and examined.Results:The inhibition rates of malignant ascites of the DDP group and the three treated groups were 74 77%,52 33%,80 11% and 92 89% respectively. The rates of tumor nodes on peritoneum were 100%, 70%, 80%, 50% and 30% respectively. All the treated groups were longer than the control group on the survival rates.Conclusion:These results suggest that the angiogenesis inhibitor TNP 470 has a strong inhibitory effect on the formation of malignant ascites.
出处 《临床肿瘤学杂志》 CAS 2003年第2期81-84,共4页 Chinese Clinical Oncology
关键词 恶性腹腔积液 血管生成抑制剂 TNP-470 小鼠 Malignant ascites Angiogenesis inhibitor TNP 470 Mice
  • 相关文献

参考文献1

二级参考文献2

共引文献2

同被引文献22

  • 1王鸿梅.TNP-470对小鼠肝癌H22腹水瘤的治疗研究[J].肿瘤研究与临床,2006,18(4):223-224. 被引量:3
  • 2Zolota V,Gerokosta A,Melachrinou M,et al.Microvessel density,proliferating activity,p53 and bcl -2 expression in in stitu ductal carcinoma of the breast[J].Anticancer Res,1999,19 (43):3269~3274.
  • 3Zhang Y,Griffith EC,Sage J,et al.Cell cycle inhibition by the anti-angiogenic agent TNP -470 is mediated by p53 and p21 WAF1/CIP1[J].Proc Natl Acad Sci USA,2000,97(12):6427~6432.
  • 4Subbaramaiah K,Dannenberg AF.Cyclooxygenase 2:a molecular target for cancer prevention and treatment[J].Trends Pharmacol Sci,2003,24:96~102.
  • 5Diaz BV,Lenoir MC,Ladoux A.Regulation of vascular endothelial growth factor expression on human keratinocytes by retinoids[J].Biol Chem,2000,275 (1):642~650.
  • 6Akre K,Ekstrom AM,Signorello LB,et al.Aspirin and risk for gastric cancer:a population-based case-control study in Sweden[J].Br J Cancer,2001,84:965~968.
  • 7Jaime LM,Kathleen ML,Alane TK,et al.Antiangiogentic and antitumor of cyclooxygenase-2 inhibitors[J].Cancer Res,2000,60:1306~1311.
  • 8Seadel M,Noack-Kunnmann K,Zhu D,et al.Growth factorinduced angiogenesis in vivo requires specific cleavage of fibrillar type Ⅰ collagen[J].Blood,2001,97 (8):2323~2332.
  • 9Calabrese L,Fleischer AB.Thalidominde:current and potential clinical applications[J].Am J Med,2000,108 (6):487~495.
  • 10Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan,fluorouracil and leucovorin for metastatic colorectal cancer[J].N Eengl J Med,2004,350:2335~2342.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部